Hvivo revenue increases by 15.5% in 2023, sets new £100M target by 2028

Hvivo, the pharmaceutical services company formerly known as Open Orphan, said revenue rose last year and raised its medium term targets to £100 million in revenue by 2028.

In a trading update for the year ended December 31st 2023, Hvivo said full year revenue was £56 million, up 15.5 per cent on the prior year. That was attributed to the continued strong delivery of human challenge trials and consulting services, and R & tax credits of £2.6 million.

Earnings before interest, tax, depreciation and amortisation margin also rose, reaching 22 per cent last year compared with 18.7 per cent in 2022. Cash was £37 million at the end of the year, up from £28.4 million at the end of 2022.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO 2024 Year in Review

    Discover how hVIVO Group’s innovative approach to human challenge trials and infectious disease expertise has shaped the future of pharmaceutical research in 2024.

    hVIVO plc

    Blood biomarkers for viral infection diagnosis and management

    Host response biomarkers to viral infections have significant potential in clinical applications, such as guiding diagnostic decisions, reducing unnecessary antibiotic use, and triggering infection control protocols or antiviral treatments. Research on these biomarkers has largely focused

    hVIVO plc

    Impact of patient perception on vaccine and drug efficacy

    Human viral challenge studies have become essential in evaluating the effectiveness of vaccines, treatments, and prophylactics, providing quicker results compared to larger Phase 2a/b field trials. hVIVO has developed various challenge agents for human use, including